Oxiracetam

Chemical identity

Oxiracetam is piracetam carrying a hydroxyl group at the 4-position of the pyrrolidinone ring. That single substitution creates a chiral centre, and commercial material is normally the racemate — a detail that matters, because the enantiomers are not equipotent in the published pharmacology.

The hydroxyl also increases polarity relative to piracetam, which affects both aqueous solubility and the compound's chromatographic behaviour.

Mechanism in research models

No definitive receptor target has been assigned, which is the recurring position across the racetam family. The best-supported findings involve positive modulation of AMPA-type glutamate receptors — enhancing the response to glutamate without acting as an agonist — and increased release of acetylcholine and glutamate in hippocampal preparations.

Effects on high-affinity choline uptake and on protein kinase C translocation have also been reported and would be consistent with a role in long-term potentiation. Oxiracetam facilitates LTP in hippocampal slice preparations, which is the most mechanistically satisfying result in its literature.

The compound crosses the blood–brain barrier and is not extensively metabolised, being largely excreted unchanged — an unusual profile that simplifies pharmacokinetic work.

What the literature establishes

The rodent behavioural literature is comparatively large for a racetam, with consistent reports of improved performance in passive avoidance and maze paradigms, particularly in models of induced cognitive impairment rather than in unimpaired animals.

Clinical work exists from the 1980s and 1990s in dementia and post-stroke cognitive impairment, mostly conducted in Italy. Results were mixed, trial sizes modest, and methodology inconsistent with contemporary standards. Oxiracetam has never been approved in the United States or the United Kingdom.

A useful pattern across this literature: effects appear most reliably in impaired systems and least reliably in healthy ones. Study designs that fail to include a challenge or lesion model frequently find nothing.

Handling, storage and solubility

The solid is typically held sealed at room temperature or below, protected from moisture; confirm the validated condition and the water content on the lot documentation. Oxiracetam is markedly hygroscopic — an open container will take up atmospheric water and the resulting mass error will propagate into every subsequent calculation.

Freely soluble in water, which makes preparation straightforward and avoids the DMSO-vehicle complications of the SARM pages on this site.

Aqueous solutions should be prepared fresh. The lactam ring is subject to slow hydrolysis, and stored solutions drift in composition without visible change.

Analytical documentation

Require HPLC purity, NMR and a water-content figure by Karl Fischer titration. For a hygroscopic compound, water content is not an optional extra — it determines how much of the weighed mass is actually the compound.

Where enantiomeric composition matters to the study design, note that standard reversed-phase HPLC does not resolve the enantiomers. Chiral analysis must be requested specifically.

References and authoritative sources

Chemical identity, regulatory status and anti-doping classification should be confirmed against primary sources rather than against this page. The records below are the ones to check first.

1. PubChem compound record (US National Library of Medicine)
2. PubMed indexed literature
3. ClinicalTrials.gov registered studies

These are database and regulatory sources. Citations to specific primary papers are being added to this page as part of ongoing scientific review; until they appear, treat the mechanism and literature sections above as a summary to verify rather than a citation of record.